There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Valeo Pharma (VPHIF – Research Report) and ADC Therapeutics (ADCT – Research Report) with bullish sentiments.
Valeo Pharma (VPHIF)
In a report released today, Stefan Quenneville from Echelon Wealth Partners reiterated a Buy rating on Valeo Pharma, with a price target of C$1.00. The company’s shares closed last Tuesday at $0.16, close to its 52-week low of $0.16.
According to TipRanks.com, Quenneville is ranked #6904 out of 8537 analysts.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Valeo Pharma with a $0.73 average price target.
See the top stocks recommended by analysts >>
ADC Therapeutics (ADCT)
H.C. Wainwright analyst Robert Burns reiterated a Buy rating on ADC Therapeutics today and set a price target of $12.00. The company’s shares closed last Thursday at $1.20, close to its 52-week low of $1.15.
According to TipRanks.com, Burns has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
ADC Therapeutics has an analyst consensus of Hold, with a price target consensus of $5.30.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
